Dopaminergic Basis of Spatial Deficits in Early Parkinson's Disease.
Dopaminergic Basis of Spatial Deficits in Early Parkinson's Disease.
复制标题
早期帕金森病空间缺陷的多巴胺能基础。
DOI：
10.1093/texcom/tgab042
复制
发表时间：
2021
影响因子：
--
通讯作者：
Lyons,KE
中科院分区：
文献类型：
--
作者：
Hanna-Pladdy,B;Pahwa,R;Lyons,KE
通过比较帕金森病(PD)患者的视觉知觉和感觉运动功能，评估了多巴胺能调节认知和运动控制的机制。帕金森病患者(n = 40)和健康对照组(n = 42)在两次单独的治疗(包括多巴胺能药物治疗)中，以不同的刺激长度(4，8，12 cm)为目标，进行计算机感知任务，并将其表现进行对比。比较了无运动需求的长度等值和宽度间隔估计的新型视觉概念任务和运动终止中估计空间偏差的任务。这些发现支持早期帕金森病患者存在空间缺陷，随着辨别难度的增加而更加明显，视觉知觉和知觉肿瘤功能的刺激长度都较短，为4厘米。多巴胺能药物对视觉操作的准确性有不利影响，特别是在长度等价性估计方面，与多巴胺能调节知觉运动功能减少朝向靶点的角度位移形成对比。帕金森病患者知觉空间准确性与运动终止性的差异结果与直接途径和通过皮质纹状体环进行性丢失多巴胺的模式相一致。未来的研究应该开发有效和敏感的感知标准化测试，并探索帕金森病的多巴胺能选择性缺陷，以优化针对该疾病的运动和认知症状的药物滴定。
Dopaminergic mechanisms regulating cognitive and motor control were evaluated comparing visuoperceptual and perceptuomotor functions in Parkinson’s disease (PD). The performance of PD patients (n = 40) was contrasted with healthy controls (n = 42) across two separate visits (onandoffdopaminergic medications) on computerized tasks of perception and aiming to a target at variable stimulus lengths (4, 8, 12 cm). Novel visuoperceptual tasks of length equivalence and width interval estimations without motor demands were compared with tasks estimating spatial deviation in movement termination. The findings support the presence of spatial deficits in early PD, more pronounced with increased discrimination difficulty, and with shorter stimulus lengths of 4 cm for both visuoperceptual and perceptumotor functions. Dopaminergic medication had an adverse impact on visuoperceptual accuracy in particular for length equivalence estimations, in contrast with dopaminergic modulation of perceptuomotor functions that reduced angular displacements toward the target. The differential outcomes for spatial accuracy in perception versus movement termination in PD are consistent with involvement of the direct pathway and models of progressive loss of dopamine through corticostriatal loops. Future research should develop validated and sensitive standardized tests of perception and explore dopaminergic selective deficits in PD to optimize medication titration for motor and cognitive symptoms of the disease.